Dyne Webinar: Positive Topline Results from DELIVER trial in Exon 51 DMD

A presentation with Dr. Doug Kerr, Chief Medical Officer at Dyne Therapeutics. Dr. Kerr shares topline results from the DELIVER clinical trial, along with new long-term data showing sustained benefits out to 24 months.

DELIVER is Dyne’s global, randomized, placebo-controlled, double-blind, Phase 1/2 trial that evaluated the safety, tolerability and efficacy of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy who have mutations in the DMD gene that are amenable to exon 51 skipping.

Recorded: Friday, December 12, 2025

Watch HERE

* Zeleciment rostudirsen is investigational or otherwise in development and has not been approved as safe or effective by the US FDA, EMA, or any other regulatory authority.